DP
PLRX icon

Diadema Partners’s Pliant Therapeutics PLRX Stock Holding History

Diadema Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144,914
Closed -$177K – 187
2025
Q4 		$177K Buy
+144,914
New +$218K 0.03% 129

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Diadema Partners's PLRX Position: Q1 2026 in Review

Diadema Partners sold out of Pliant Therapeutics (PLRX) in Q1 2026, closing a stake of 144,914 shares — an estimated $177K sold.

Diadema Partners first reported a position in PLRX in Q4 2025 and held it in 1 quarter. The position peaked at $177K in Q4 2025. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Diadema Partners reported no remaining Pliant Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 144,914 Pliant Therapeutics shares in Q1 2026, an estimated $177K.
  • Diadema Partners first reported a position in Pliant Therapeutics in Q4 2025 and held it in 1 quarter.
  • Diadema Partners's Pliant Therapeutics position peaked at $177K in Q4 2025.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.